Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FS... Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States. Mehr anzeigen
New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth...
Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.075 | 0.900360144058 | 8.33 | 8.5 | 7.87 | 1316023 | 8.1700047 | CS |
| 4 | 1.385 | 19.7293447293 | 7.02 | 8.74 | 6.94 | 1400646 | 7.9425304 | CS |
| 12 | 1.775 | 26.7722473605 | 6.63 | 8.74 | 6.42 | 1197671 | 7.39058823 | CS |
| 26 | 2.645 | 45.9201388889 | 5.76 | 8.74 | 5.11 | 1240109 | 6.4692234 | CS |
| 52 | -0.815 | -8.83947939262 | 9.22 | 10.05 | 4.71 | 1657963 | 6.76170071 | CS |
| 156 | -16.055 | -65.6377759608 | 24.46 | 24.55 | 4.07 | 2374232 | 9.96613887 | CS |
| 260 | 2.305 | 37.7868852459 | 6.1 | 33.9715 | 4.07 | 2577001 | 12.86498335 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
